SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes

NCT ID: NCT04964024

Last Updated: 2022-07-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1293 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-15

Study Completion Date

2022-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease.

Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Residents in Nursing homes

SARS-CoV-2 antibodies

Intervention Type DIAGNOSTIC_TEST

Analysis of the results of the serological response to COVID-19 and/or Vaccine

Health professionals in Nursing homes

SARS-CoV-2 antibodies

Intervention Type DIAGNOSTIC_TEST

Analysis of the results of the serological response to COVID-19 and/or Vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SARS-CoV-2 antibodies

Analysis of the results of the serological response to COVID-19 and/or Vaccine

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For Residents:

* Living in one of the 9 Nursing Homes that participate in this study
* Having a SARS-COV-2 post vaccination serology.
* Having no objection for using the results of the serology for the purpose of this analysis

For Health Professionals:

* Working in one of the 9 Nursing Homes that participate in this study,
* Having a SARS-COV-2 post vaccination serology.
* Having no objection for using the results of the serology for the purpose of this analysis

Exclusion Criteria

* None
Minimum Eligible Age

20 Years

Maximum Eligible Age

110 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Hospital, Nancy, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pr Athanase BENETOS

Athanase Benetos, Clinical Professor, Head of the Dpt of Geriatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU de Nancy, Université de Lorraine

Vandœuvre-lès-Nancy, US and Canada Only, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EHPAD-COVID-19

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.